Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8231825 | 0.93 | PDE10A (0.70) | PDE10APDE3APDGFRBNTSR1HTR1A | |
| SCHEMBL8229176 | 0.91 | PDE10A (0.63) | PDE10APDE3APDGFRB | |
| SCHEMBL4778206 | 0.91 | PDE10A (0.63) | PDE10APDE3APDGFRB | |
| SCHEMBL4973098 | 0.84 | PDE10A (0.61) | PDE10APDE3APDGFRB | |
| SCHEMBL4971994 | 0.84 | PDE10A (0.61) | PDE10APDE3APDGFRB | |
| SCHEMBL4972750 | 0.84 | PDE10A (0.61) | PDE10APDE3APDGFRB | |
| SCHEMBL5653836 | 0.83 | PDE10A (0.62) | PDE10APDE3APDGFRBNTSR1HTR1A | |
| SCHEMBL14367681 | 0.83 | PDE10A (0.62) | PDE10APDE3APDGFRBNTSR1HTR1A | |
| SCHEMBL4969563 | 0.82 | PDE10A (0.56) | PDE10APDGFRBNTSR1HTR1AHTR7 | |
| SCHEMBL8233340 | 0.81 | PDE10A (0.54) | PDE10APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991540-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| WO-2007098214-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | PDE10A 2/4885PDE3A 7/4885PDGFRB 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.